سعر دومبيدون 30 مجم 6 أقماع 2022

Arab Drug Company — Dompidone 30mg 6 supp.

• Relief of the symptoms of nausea and vomitingPopulation: Adults and adolescents ≥12 years and ≥35 kg (Motilium oral tablets SmPC)HPRA / medicines.ie

• Include dry mouth, diarrhoea, headache, somnolence, anxiety; not known: ventricular arrhythmias, QTc prolongation, torsade de pointes, sudden cardiac death, extrapyramidal symptoms, galactorrhoea/gynaecomastia.General active-ingredient information · HPRA / medicines.ie

• Hypersensitivity; prolactinoma; GI haemorrhage/obstruction/perforation; moderate–severe hepatic impairment; known QTc prolongation, significant electrolyte disturbance, or CHF; co-administration with QT-prolonging drugs (except apomorphine under strict conditions) or potent CYP3A4 inhibitors; confirmed/suspected pheochromocytoma.General active-ingredient information · HPRA / medicines.ie

• Associated with QT prolongation and rare ventricular arrhythmia/sudden cardiac death risk; higher risk >60 y, >30 mg/day, or with QT-prolonging/CYP3A4-inhibitor drugs. Stop if arrhythmia symptoms.General active-ingredient information · HPRA / medicines.ie

• Potent CYP3A4 inhibitors and QT-prolonging drugsMajorContraindicated: potent CYP3A4 inhibitors and QT-prolonging medicines increase domperidone exposure and/or arrhythmia risk (Motilium IE SmPC).HPRA / medicines.ie

• Limited post-marketing pregnancy data; use only when justified by anticipated benefit.General active-ingredient information · HPRA / medicines.ie
• Excreted in human milk (<0.1% maternal weight-adjusted dose); decide whether to discontinue breastfeeding or therapy.General active-ingredient information · HPRA / medicines.ie

• Domperidone: Blocks peripheral D2 receptors in the chemoreceptor trigger zone and GI tract; limited CNS penetration.